127 related articles for article (PubMed ID: 16314808)
1. Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation.
Mitsuhata N; Fujita R; Ito S; Mannami M; Keimei K
Transplantation; 2005 Nov; 80(9):1355. PubMed ID: 16314808
[No Abstract] [Full Text] [Related]
2. Rituximab in pediatric renal transplantation: a treatment for allograft rejection with B-cell infiltrates?
Zand MS
Am J Transplant; 2008 Dec; 8(12):2489-90. PubMed ID: 19032220
[No Abstract] [Full Text] [Related]
3. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient.
Kumar D; Gourishankar S; Mueller T; Cockfield S; Weinkauf J; Vethanayagam D; Humar A
Transpl Infect Dis; 2009 Apr; 11(2):167-70. PubMed ID: 18803617
[TBL] [Abstract][Full Text] [Related]
4. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
5. Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia.
Basse G; Ribes D; Kamar N; Esposito L; Rostaing L
Clin Nephrol; 2006 Nov; 66(5):395-6. PubMed ID: 17140171
[No Abstract] [Full Text] [Related]
6. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
7. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.
Terrier B; Ittah M; Tourneur L; Louache F; Soumelis V; Lavie F; Casadevall N; Candon S; Hummel A; Mariette X; Buzyn A
Haematologica; 2007 Feb; 92(2):e20-3. PubMed ID: 17405749
[TBL] [Abstract][Full Text] [Related]
8. Neutropenia after rituximab treatment: new insights on a late complication.
Wolach O; Shpilberg O; Lahav M
Curr Opin Hematol; 2012 Jan; 19(1):32-8. PubMed ID: 22080846
[TBL] [Abstract][Full Text] [Related]
9. Single-dose rituximab as induction in renal transplantation.
van den Hoogen MW; Hilbrands LB
Transplantation; 2010 May; 89(10):1295; author reply 1295. PubMed ID: 20555227
[No Abstract] [Full Text] [Related]
10. Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation--single-center study.
Ishida H; Inui M; Furusawa M; Tanabe K
Transpl Immunol; 2013 Mar; 28(2-3):93-9. PubMed ID: 23353568
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for humoral rejection after kidney transplantation: an update.
Rostaing L; Guilbeau-Frugier C; Kamar N
Transplantation; 2009 Apr; 87(8):1261. PubMed ID: 19384176
[No Abstract] [Full Text] [Related]
12. [Rituximab: mabthera].
Lapeyre H; Joly P
Ann Dermatol Venereol; 2007 Dec; 134(12):968-71. PubMed ID: 18166919
[No Abstract] [Full Text] [Related]
13. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.
Tydén G; Genberg H; Tollemar J; Ekberg H; Persson NH; Tufveson G; Wadström J; Gäbel M; Mjörnstedt L
Transplantation; 2009 May; 87(9):1325-9. PubMed ID: 19424032
[TBL] [Abstract][Full Text] [Related]
14. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases.
Rios-Fernández R; Gutierrez-Salmerón MT; Callejas-Rubio JL; Fernández-Pugnaire M; Ortego-Centeno N
Br J Dermatol; 2007 Dec; 157(6):1271-3. PubMed ID: 17916218
[No Abstract] [Full Text] [Related]
15. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in highly sensitized kidney transplant recipients.
Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis.
Zhao YG; Shi BY; Qian YY; Bai HW; Xiao L; He XY
Int Urol Nephrol; 2014 Jun; 46(6):1225-30. PubMed ID: 24242738
[TBL] [Abstract][Full Text] [Related]
18. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
[TBL] [Abstract][Full Text] [Related]
19. Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy.
Chung BH; Yun JT; Ha SE; Kim JI; Moon IS; Choi BS; Park CW; Kim YS; Yang CW
Transpl Infect Dis; 2013 Dec; 15(6):559-68. PubMed ID: 24011062
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for patients with idiopathic thrombocytopenic purpura.
Peñalver FJ; Cabrera JR
Ann Intern Med; 2007 Aug; 147(4):281; author reply 281-2. PubMed ID: 17709765
[No Abstract] [Full Text] [Related]
[Next] [New Search]
